Insmed (INSM) Non-Current Debt (2012 - 2026)
Insmed (INSM) recorded quarterly Non-Current Debt of $542.2 million in Q1 2026, little changed quarter-over-quarter from $541.0 million in Q4 2025, and down 50.93% on a YoY basis from $1.1 billion in Q1 2025.
Insmed (INSM) Non-Current Debt (2012 - 2026) Analysis & Trends
Insmed's Non-Current Debt history runs 15 years deep, the most recent figure standing at $542.2 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 50.93% year-over-year to $542.2 million; the TTM figure through Mar 2026 stood at $542.2 million (down 50.93% YoY), while the FY2025 annual figure was $541.0 million, down 50.97% from the prior year.
- Non-Current Debt was $542.2 million for Q1 2026 at Insmed, roughly flat from $541.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.2 billion in Q4 2023 to a low of $538.5 million in Q2 2025.
- Historically, Non-Current Debt has averaged $897.8 million across 5 years, with a median of $946.8 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt jumped 116.6% in 2022, then plunged 50.97% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $1.1 billion in 2022, then climbed by 2.67% to $1.2 billion in 2023, then dropped by 4.49% to $1.1 billion in 2024, then slumped by 50.97% to $541.0 million in 2025, then rose by 0.23% to $542.2 million in 2026.
- The last three Non-Current Debt figures came in at $542.2 million (Q1 2026), $541.0 million (Q4 2025), and $539.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 542.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 542.22 Mn |
| Mar 31, 2026 | 542.22 Mn |
| Dec 31, 2025 | 540.96 Mn |
| Dec 31, 2025 | 540.96 Mn |
| Sep 30, 2025 | 539.72 Mn |
| Sep 30, 2025 | 539.72 Mn |
| Jun 30, 2025 | 538.51 Mn |
| Jun 30, 2025 | 538.51 Mn |
| Mar 31, 2025 | 1.11 Bn |
| Mar 31, 2025 | 1.11 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Sep 30, 2024 | 954.83 Mn |
| Sep 30, 2024 | 954.83 Mn |
| Jun 30, 2024 | 946.83 Mn |
| Jun 30, 2024 | 946.83 Mn |
| Mar 31, 2024 | 939.08 Mn |
| Mar 31, 2024 | 939.08 Mn |
| Dec 31, 2023 | 1.16 Bn |
| Dec 31, 2023 | 1.16 Bn |